Nektar Therapeutics (NKTR) Misses Q1 Views on Top and Bottom
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $63.65 +2.61%
Revenue Growth %: -7.1%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: -7.1%
Financial Fact:
Cost of goods sold: 7.03M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 loss of $0.33, $0.06 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $17.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
- SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
